An observational study in Lung Caner, sponsored by Shengjing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Shengjing Hospital · Observational
Modifiable risk factors, including smoking, alcohol consumption, and diet, play critical roles in cancer progression and patient prognosis. In patients diagnosed with lung cancer, these risk factors not only directly modulate host metabolism and immune regulation, but also exert indirect effects by altering the internal milieu, such as the gut microbiota-potentially exerting a profound impact on long-term clinical trajectories.
Leveraging a well-characterized, longitudinally followed cohort of confirmed lung cancer patients, this study systematically assesses habitual dietary intake, emotional well-being, lifestyle behaviors, and related variables using validated instruments, including the Food Frequency Questionnaire (FFQ). Furthermore, the study integrates multidimensional biomarker profiling across tumor tissue, blood, urine, and fecal samples. By linking exposure profiles, multi-omics data, and long-term clinical follow-up records, this project aims to:
Ultimately, this study aims to establish evidence-based healthy lifestyle recommendations for patients and provide healthcare professionals with translational insights to inform precision nutrition and targeted intervention strategies across the continuum of lung cancer care.
Shengjing Hospital is the lead sponsor of 127 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Starting in February 2019, patients with histologically or cytologically confirmed lung cancer who received treatment and follow-up at Shengjing Hospital of China Medical University were enrolled in this study. Clinical and demographic characteristics were extracted from the electronic medical record (EMR) system, lifestyle habits and related exposure data were collected using a validated Food Frequency Questionnaire (FFQ), and high-quality follow-up was conducted on a regular basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6-Month Progression-Free Survival (PFS) Rate
Time frame: 6 months
Overall Survival (OS)
Time frame: From enrollment through study completion, up to 10 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.